在肝细胞癌中肝脏微环境和治疗耐药性
Kosar Rahi1, Mahdi Hedayati2, Zahra Hendi1
1Department of Animal Biology-Cell and Developmental, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
肝细胞癌 (HCC) 耐药性是一个重大挑战. 瘤微环境 (TME) 和其细胞外基质 (ECM) 显著促进HCC患者的化疗耐药性.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 生物化学 生化学
背景情况:
- 肝细胞癌 (HCC) 由于晚期诊断,治疗耐药性和高复发率带来了重大挑战.
- 化疗仍然是晚期HCC的主要治疗方法,尽管有免疫疗法和向治疗等新兴疗法.
- 瘤微环境 (TME),包括细胞和细胞外基质 (ECM),在治疗结果中起着至关重要的作用.
研究的目的:
- 审查了解HCC的TME的最新进展.
- 阐明TME对肝细胞癌药物耐药性的贡献.
- 为了解TME介导化学抵抗的机制提供见解.
主要方法:
- 关于HCC TME和药物耐药性的最新研究的文献综述.
- 分析研究研究TME组件对治疗疗效的影响.
- 综合有关TME影响HCC治疗的物理和生化因素的发现.
主要成果:
- 在TME内的瘤异质性有助于抵抗化疗和其他疗法.
- 动态的ECM受细胞因子和结构成分的影响,可以促进对治疗剂的耐药性.
- 在TME的物理变化,包括pH,缺氧,剪切应力和性,诱导HCC细胞的抗性.
结论:
- 在HCC中,TME是药物耐药性发展的关键因素.
- 了解TME的作用对于开发克服化学抗药性的策略至关重要.
- 针对TME可能为管理HCC提供新的治疗途径.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
08:40A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
Published on: August 7, 2020
相关概念视频
Treatment Resistant Cancers
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
